A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. We have identified the pyrazolo[3,4-d]pyrimidine A-420983 (compound 7) as a potent inhibitor of lck. A-420983 exhibits oral efficacy in animal models of delayed-type hypersensitivity and organ transplant rejection. 